Advertisement

Current Bladder Dysfunction Reports

, Volume 3, Issue 1, pp 41–46 | Cite as

How to choose the initial drug treatment for overactive bladder

  • Scott A. MacDiarmidEmail author
Article
  • 39 Downloads

Abstract

Antimuscarinics are the treatment of choice for patients suffering from overactive bladder syndrome (OAB). Clinical experience and the literature support the efficacy, tolerability, and safety of each agent. With increasing data and educational and marketing efforts, many health care providers are uncertain which antimuscarinic should be prescribed first. It is important to recognize that there is not one superior agent, and that the individual response to each antimuscarinic is highly variable. This paper uses peer-reviewed literature to elucidate various agents with respect to efficacy, tolerability, and safety, to help readers understand the pros and cons associated with each drug so they may better manage patients with OAB.

Keywords

Lower Urinary Tract Symptom Overactive Bladder Oxybutynin Tamsulosin Tolterodine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Abrams P, Cardozo L, Magnus F, et al.: The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Urology 2003, 61:37–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Stewart WF, Van Rooyen JB, Cundiff GW, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20:327–326.PubMedGoogle Scholar
  3. 3.
    Abrams P, Kelleher CJ, Kerr LA, Rogers RG: Overactive bladder significantly affects quality of life. Am J Manag Care 2000, 6:S580–S590PubMedGoogle Scholar
  4. 4.
    Brading AF: A myogenic basis for the overactive bladder. Urology 1997, 50:57–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Fantl J, Newman D, Colling J, et al.: Clinical Practice Guideline Number 2: Urinary Incontinence in Adults: Acute and Chronic Management. Rockville, MD: US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1996 Update. [AHCPR publication 96-0682.]Google Scholar
  6. 6.
    Diokno AC, Appell RA, Sand PK, et al.: Prospective randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003, 78:687–695.PubMedCrossRefGoogle Scholar
  7. 7.
    Chapple CR, Martinez-Garcia R, Selvaggie L, et al.: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005, 48:464–470.PubMedGoogle Scholar
  8. 8.
    Dmochowski RR, PK Sand, Zinner NR, et al.: Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003. 62:237–242.PubMedCrossRefGoogle Scholar
  9. 9.
    Anderson RU, Mobley D, Blank B, et al.: Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999, 161:1809–1812.PubMedCrossRefGoogle Scholar
  10. 10.
    Gleason DM, Susset J, White C, et al.: Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Urology 1999, 54:420–423.PubMedCrossRefGoogle Scholar
  11. 11.
    Versi E, Appell R, Mobley D, et al.: Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000, 95:718–721.PubMedCrossRefGoogle Scholar
  12. 12.
    MacDiarmid SA, Anderson RU, Armstrong RB, et al.: Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J Urol 2005, 174:1301–1305.PubMedCrossRefGoogle Scholar
  13. 13.
    O’Leary M, Erickson JR, Smith CP, et al.: Changes in voiding patterns in multiple sclerosis patients with controlled-release oxybutynin. Int J MS Care 2002, 4:116–119.Google Scholar
  14. 14.
    O’Leary M, Erickson JR, Smith CP, et al.: The effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injured patients. J Spinal Cord Med 2003, 26:159–162.PubMedGoogle Scholar
  15. 15.
    Steers W, Corcos J, Foote J, et al.: An investigation of dose titration with darifenacin, an M-3 selective receptor antagonist. BJU Int 2005, 95:580–586.PubMedCrossRefGoogle Scholar
  16. 16.
    Cardozo L, Lisec M, Millard R, et al.: Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004, 172:1919–1924.PubMedCrossRefGoogle Scholar
  17. 17.
    Chapple CR, Rechberger T, Al-Shukri S, et al.: Randomized, double-blind placebo-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004, 93:303–310.PubMedCrossRefGoogle Scholar
  18. 18.
    Rackley R, Weiss J, Rovner E, et al.: Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006, 67:731–736.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001, 57:414–421.PubMedCrossRefGoogle Scholar
  20. 20.
    Zobrist RH, Quan D, Thomas HM, et al.: Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Rev 2003, 20:103–109.CrossRefGoogle Scholar
  21. 21.
    Dmochowski RR, Davilla GW, Zinner NR, et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002, 168:580–586.PubMedCrossRefGoogle Scholar
  22. 22.
    Flicker C, Ferris SH, Serby M: Hypersensitivity to scopolamine in the elderly. Psychopharmacology 1992, 107:437–441.PubMedCrossRefGoogle Scholar
  23. 23.
    Todorova A, Vonderheid-Guth B, Dimpfel W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001, 41:636–644.PubMedCrossRefGoogle Scholar
  24. 24.
    Staskin DR, Harnett MD: Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 2004, 5:423–426.PubMedCrossRefGoogle Scholar
  25. 25.
    Napier C, Gupta P: Darifenacin is selective for the human recombinant M3 receptor subtype [abstract]. Neurourol Urodyn 2002, 21:A445.Google Scholar
  26. 26.
    Anagnostaras SG, Murphy GC, Hamilton SE, et al.: Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003, 6:51–58.PubMedCrossRefGoogle Scholar
  27. 27.
    Drachman DA, Noffsinger D, Sahakian BJ, et al.: Aging, memory, and the cholinergic system: a study of dichotic listening. Neurobiol Aging 1980, 1:39–43.PubMedCrossRefGoogle Scholar
  28. 28.
    Lipton RB, Kolodner K, Wesnes K: Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005, 173:493–498.PubMedCrossRefGoogle Scholar
  29. 29.
    Kay G, Crook T, Rekeda L, et al.: Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50 :317–326.Google Scholar
  30. 30.
    Kay G, Kardiasmenos K, Crook T: Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects [abstract]. Presented at the International Continence Society Meeting. Christchurch, New Zealand; November 27–December 1, 2006.Google Scholar
  31. 31.
    Serra DB, Affrime MB, Bedigian MP, et al.: QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005, 45:1038–1047.PubMedCrossRefGoogle Scholar
  32. 32.
    Napier C, Gupta P: Darifenacin is selective for the human recombinant M3 receptor subtype [abstract 445]. Presented at the 32nd Annual Meeting of the International Continence Society. Heidelberg, Germany; August 28–30, 2002.Google Scholar
  33. 33.
    Abrams P, Kaplan S, Millard R: Tolterodine treatment is safe in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity (DO). Neurourol Urodyn 2001, 20:547–548.Google Scholar
  34. 34.
    Kaplan S, Walmsley K, Te A: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005, 174:2273–2275.PubMedCrossRefGoogle Scholar
  35. 35.
    MacDiarmid S, Chen A, Tu Nora, et al.: Effects of tamsulosin and extended-release oxybutynin on lower urinary tract symptoms in men [abstract 1639]. Presented at the American Urological Association Annual Meeting. Atlanta, GA; May 20–25, 2006.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Alliance Urology SpecialistsBladder Control and Pelvic Pain CenterGreensboroUSA

Personalised recommendations